Verrica Pharmaceuticals Inc (VRCA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.30-1.12%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · VRCA
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(12.4) + peer(0.2*-3.3) + term(0.0) → 3.67% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On August 6, 2026, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2026, as well as information regarding a conference call to discuss these financial results and the Registrant’s recent corporate highlights. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On May 12, 2026, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter ended March 31, 2026. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…
Results of Operations and Financial Condition. On March 11, 2026, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securi…
Results of Operations and Financial Condition. On November 14, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025, as well as information regarding a conference call to discuss the financials and business updates. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this…
Results of Operations and Financial Condition. On August 12, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) issued a press release announcing its financial results for the three and six months ended June 30, 2025, as well as information regarding a conference call to discuss the financials and business updates. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.…
Results of Operations and Financial Condition. On May 13, 2025, Verrica Pharmaceuticals Inc. (the “ Company ”) issued a press release announcing its financial results for the three months ended March 31, 2025, as well as information regarding a conference call to discuss the financials and business updates. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Ex…
Results of Operations and Financial Condition. On March 11, 2025, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securi…
Results of Operations and Financial Condition. On November 4, 2024, Verrica Pharmaceuticals Inc. (the “ Company ) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2024. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the…
Results of Operations and Financial Condition. On August 14, 2024, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2024. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Sec…
Results of Operations and Financial Condition. On May 13, 2024, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter ended March 31, 2024. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes o…
Results of Operations and Financial Condition. On February 29, 2024, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “file…
Results of Operations and Financial Condition. On November 9, 2023, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and nine months ended September 30, 2023. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deeme…
Results of Operations and Financial Condition. On August 8, 2023, Verrica Pharmaceuticals Inc. (the “ Registrant ”) issued a press release announcing its financial results for the quarter and six months ended June 30, 2023. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed…